RECURSION PHARMACEUTICALS, INC. (RXRX) › Operating IncomeRECURSION PHARMACEUTICALS, INC. (RXRX) — Operating IncomeAnnual figures by fiscal year, from SEC filings.2019: -$62.44M2020: -$84.61M2021: -$182.78M2022: -$245.73M2023: -$350.06M2024: -$479.00M2025: -$648.13M-$648.13M2019Operating Income (USD)2025Fiscal YearOperating IncomeChange YoY2025-$648.13M-35.3%2024-$479.00M-36.8%2023-$350.06M-42.5%2022-$245.73M-34.4%2021-$182.78M-116.0%2020-$84.61M-35.5%2019-$62.44M—Other metrics: RevenueCost of RevenueGross ProfitNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share